Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue

1984, Leuprolide versus diethylstilbestrol for metastatic prostate cancer, N Engl J Med, 311, 1261, 10.1056/NEJM198411083111922 Klijn, 1982, Treatment with a luteinizing hormone releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer, Lancet, 1, 1213, 10.1016/S0140-6736(82)92339-X Redding, 1983, Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones, Proc Natl Acad Sci USA, 80, 1078, 10.1073/pnas.80.4.1078 Hsueh, 1985, Gonadotropin-releasing hormone as a paracrine hormone and neurotransmitter in extrapituitary sites, J Steroid Biochem, 23, 757, 10.1016/S0022-4731(85)80011-X Maruo, 1985, Antigonadotropic actions of GnRH agonist on ovarian cells in vivo and in vitro, J Steroid Biochem, 23, 765, 10.1016/S0022-4731(85)80012-1 Knecht, 1985, Gonadotropin-releasing hormone as a modulator of ovarian function, J Steroid Biochem, 23, 771, 10.1016/S0022-4731(85)80013-3 Dufau, 1985, Fetal Leydig cell culture—an in vitro system for the study of trophic hormone and GnRH receptors and actions, J Steroid Biochem, 23, 743, 10.1016/S0022-4731(85)80010-8 Bramley, 1985, Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties, and luteal phase levels, J Clin Endocrinol Metab, 61, 834, 10.1210/jcem-61-5-834 Emons, 1989, Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata, Eur J Cancer Clin Oncol, 25, 215, 10.1016/0277-5379(89)90011-4 Parmar, 1988, Response to D-Trp-6-luteinizing hormone releasing hormone (decapeptyl) microcapsules in advanced ovarian cancer, Br Med J, 296, 1229, 10.1136/bmj.296.6631.1229 Runge, 1986, In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy, Cancer Chemother Pharmacol, 16, 58, 10.1007/BF00255287 Lazo, 1984, Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro, Cancer Res, 44, 2266 Sutherland, 1980, High-affinity antioestrogen binding site distinct from the oestrogen receptor, Nature, 288, 273, 10.1038/288273a0 Kuhnel, 1987, Androgen receptor predominance in human ovarian carcinomas, J Steroid Biochem, 26, 393, 10.1016/0022-4731(87)90106-3 Beechman, 1988, Tamoxifen is effective as second line therapy for certain patients with advanced, chemotherapy-resistant epithelial ovarian cancer: a gynecologic oncology group study of 105 patients, Proc Am Soc Clin Oncol, 7, 135 Resnicoff, 1988, Combination of a somatostatin analogue, sandostatin, tamoxifen and estradiol induces an important lytic effect on estrogen receptor positive breast cancer cell lines, Proc Am Assoc Cancer Res, 29, 234